Please assess the completion status of the following clinical trial:

Trial Title: Effect of Montelukast on Remodelling Markers in Asthmatic Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnostic criteria: the classification of asthma will be based on clinical history and examination and pulmonary function parameters, according to international guidelines.~* Stage and/or severity of condition: atopic children with mild intermittent asthma will be enrolled. Atopy will be evaluated by skin-prick test to common allergens in the area.~* Confirmatory physical and laboratory findings:~* Age: ranging in age 6 to 14 years.~* Evidence of susceptibility to the disease under study~* Patients have not used ICS during 3-month period prior to study entry~Exclusion Criteria:~* Patients will be excluded if they had used oral steroids in the last month.~* Patients will be excluded if they had acute or chronic lung diseases other than asthma, upper or lower airway infection in the previous 3 weeks or during the trial, acute asthma exacerbation, or had used oral steroids in the last month.~* Patients will be excluded if they had acute or chronic lung diseases other than asthma, upper or lower airway infections in the previous 3 weeks or during the trial, acute asthma exacerbation, or had used oral steroids in the last month.

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Montelukast (Type: ACTIVE_COMPARATOR): Montelukast chewing tablets once daily per os, plus inhaled short acting beta2 agonist as needed
- placebo (Type: PLACEBO_COMPARATOR): placebo chewing tablets per os once daily, plus inhaled short acting beta 2 agonist as needed

Based on this trial design, predict the completion outcome and termination type (if applicable).